CHAPTER 1. INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2. RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3. MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4. MARKET DYNAMICS
4.1. Market Drivers & Opportunities
4.1.1. Favourable reimbursement and government support
4.1.2. Increasing prevalence of chronic diseases
4.1.3. Increasing number of regulatory approvals
4.1.4. Patent expiry of biologics to drive the demand for biosimilar
4.2. Market Restraints & Challenges
4.2.1. Needle-stick injuries & misuse of the injection pen
4.2.2. Preference for alternative drug delivery modes
CHAPTER 5. GLOBAL INJECTION PEN MARKET – BY TYPE
5.1. Reusable injection pen
5.2. Disposable injection pen
CHAPTER 6. GLOBAL INJECTION PEN MARKET – BY THERAPY
6.1. Osteoporosis
6.2. Growth Hormone Therapy
6.3. Fertility
6.4. Diabetes
6.4.1. Insulin
6.4.2. Glucagon-Like Peptide-1
6.5. Others
CHAPTER 7. GLOBAL INJECTION PEN MARKET – BY END USER
7.1. Hospitals & Clinics
7.2. Home Care
7.3. Others
CHAPTER 8. GLOBAL INJECTION PEN MARKET - BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.2.3. Mexico
8.2.4. Costa Rica
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Chile
8.3.4. Columbia
8.3.5. Others
8.4. Europe
8.4.1. U.K.
8.4.2. Germany
8.4.3. France
8.4.4. Italy
8.4.5. Spain
8.4.6. Russia
8.4.7. Netherlands
8.4.8. Switzerland
8.4.9. Poland
8.4.10. Others
8.5. APAC
8.5.1. China
8.5.2. Japan
8.5.3. India
8.5.4. South Korea
8.5.5. Australia & New Zealand
8.5.6. Malaysia
8.5.7. Singapore
8.5.8. Others
8.6. Middle East & Africa
8.6.1. UAE
8.6.2. Saudi Arabia
8.6.3. Iran
8.6.4. Iraq
8.6.5. Qatar
8.6.6. South Africa
8.6.7. Algeria
8.6.8. Morocco
8.6.9. Nigeria
8.6.10. Egypt
8.6.11. Others
CHAPTER 9. GLOBAL INJECTION PEN MARKET - COMPANY PROFILES
9.1. Becton, Dickinson and Company
9.2. Sanofi S.A.
9.3. Owen Mumford Ltd.
9.4. Novo Nordisk A/S
9.5. Wockhardt Ltd.
9.6. Eli Lilly and Company
9.7. Jiangsu Delfu Co.
9.8. AstraZeneca, PLC.
9.9. Biocon, Ltd.
9.10. Pfizer, Inc.
9.11. Merck Group
9.12. F.Hoffman-La Roche AG
9.13. Haselmeier GmbH & Co. KG
CHAPTER 10. GLOBAL INJECTION PEN MARKET - COMPETITIVE LANDSCAPE
10.1. Market Share Analysis
10.2. Strategies adopted by top companies
10.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 11. MARKET INSIGHTS
11.1. Industry Experts Insights
11.2. Analysts Opinions
11.3. Investment Opportunities
CHAPTER 12. APPENDIX
12.1. List of Tables
12.2. List of Figures
